FDA Approves For Permanent Treatment Of Advanced Heart Failure Assist Device Pioneered By Texas Heart Institute At St. Luke’s Episcopal Hospital
The federal Food and Drug Administration has approved a continuous-flow heart-assist device pioneered at the Texas Heart Institute (THI) at St. Luke’s Episcopal Hospital (SLEH) for use as a permanent treatment for advanced heart failure. The approval of the pump device, the HeartMate II, follows several years of clinical trials and is seen as a major milestone for patients in the United States.
For the full story, Click Here
- Sunshine Heart C-Pulse implantable heart assist device passes 5-year durability testing
- FDA gives unconditional IDE approval to Berlin Heart’s EXCOR
- Thoratec HeartMate II gets FDA nod
- Acorda Therapeutics Announces Receipt Of NIH Grant For Development Of GGF2 In Heart Failure
